Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clomipramine hydrochloride
Drug ID BADD_D00500
Description Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Clomipramine may be used to treat obsessive-compulsive disorder and disorders with an obsessive-compulsive component (e.g. depression, schizophrenia, Tourette’s disorder). Unlabeled indications include panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy, autistic disorder, trichotillomania, onchophagia, stuttering, premature ejaculation, and premenstrual syndrome. Clomipramine is rapidly absorbed from the gastrointestinal tract and demethylated in the liver to its primary active metabolite, desmethylclomipramine.
Indications and Usage Unlabeled indications include: depression, panic disorder, chronic pain (e.g. central pain, idiopathic pain disorder, tension headache, diabetic peripheral neuropathy, neuropathic pain), cataplexy and associated narcolepsy (limited evidence), autistic disorder (limited evidence), trichotillomania (limited evidence), onchophagia (limited evidence), stuttering (limited evidence), premature ejaculation, and premenstrual syndrome.
Marketing Status Prescription; Discontinued
ATC Code N06AA04
DrugBank ID DB01242
KEGG ID D00811
MeSH ID D002997
PubChem ID 68539
TTD Drug ID D0ZS8P
NDC Product Code 16714-850; 52817-280; 71205-911; 51927-4511; 45562-1742; 60429-289; 10135-700; 10135-699; 0406-8806; 46708-407; 16571-683; 0781-2027; 70756-407; 51407-317; 16571-685; 16714-849; 10135-698; 52817-281; 70771-1014; 0378-3050; 67763-113; 63629-1111; 72664-214; 60429-288; 70771-1012; 51407-316; 52817-282; 46708-408; 51672-4013; 72664-216; 68084-790; 0832-0630; 0904-7039; 16571-684; 0406-9907; 16714-851; 70710-1066; 70771-1013; 70756-405; 0378-3025; 69315-167; 70710-1067; 71205-912; 0406-8807; 0378-3075; 51407-315; 71554-024; 51672-4012; 71205-910; 68084-818; 72664-215; 62332-409; 0406-9908; 27241-212; 0406-8808; 62332-407; 0406-9906; 54154-004; 42571-344; 60429-287; 49452-2149; 0832-0632; 0832-0631; 69315-165; 0781-2037; 27241-211; 46708-409; 69315-166; 38779-2256; 69575-4013; 42571-342; 70710-1065; 43063-257; 51672-4011; 70756-406; 27241-210; 0904-7038; 62332-408; 42571-343
Synonyms Clomipramine | Chlomipramine | Chlorimipramine | Hydiphen | Clomipramine Maleate (1:1) | Clomipramine Monohydrochloride | Monohydrochloride, Clomipramine | Anafranil | Clomipramine Hydrochloride | Hydrochloride, Clomipramine
Chemical Information
Molecular Formula C19H24Cl2N2
CAS Registry Number 17321-77-6
SMILES CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperventilation22.02.01.006; 19.01.02.004--Not Available
Hypoaesthesia17.02.06.023--Not Available
Hypokalaemia14.05.03.002--
Hypokinesia17.01.02.009--Not Available
Hypothyroidism14.11.01.012; 05.02.03.001--
Hypoventilation22.02.01.007--Not Available
IIIrd nerve paralysis17.04.02.003; 06.05.02.011--Not Available
Ileus paralytic07.02.05.001--Not Available
Illusion19.10.02.005--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection susceptibility increased10.02.01.046; 11.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intestinal obstruction07.13.01.002--Not Available
Irritability19.04.02.013; 08.01.03.011--
Irritable bowel syndrome19.24.01.003; 07.02.04.003--Not Available
Keratitis06.04.02.002--
Lacrimation disorder06.08.02.010--Not Available
Laryngitis22.07.03.001; 11.01.13.001--
Laryngospasm22.04.02.002--
Leukaemoid reaction01.02.01.001--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Memory impairment19.20.01.003; 17.03.02.003--
Menstrual disorder21.01.01.004--Not Available
Micturition disorder20.02.02.005--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mouth ulceration07.05.06.004--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 11 Pages